VIVUS Inc (VVUS.O)
28 Aug 2015
- A U.S. subsidiary of Actavis PLC and rival drugmaker Vivus Inc have asked a federal judge to weigh in on a dispute over whether a Vivus in-house attorney should be allowed to work on a patent lawsuit over Vivus' weight-loss drug Qsymia and on other matters related to that drug at the same time.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥5,966||+131.00|
|Eisai Co., Ltd (4523.T)||¥8,045||+331.00|
|Novo Nordisk A/S (NOVOb.CO)||kr.369.50||-0.60|
|Pfizer Inc. (PFE.N)||$32.66||-0.60|
|Merck & Co., Inc. (MRK.N)||$55.37||+0.42|
|Roche Holding Ltd. (ROG.VX)||CHF263.20||-3.80|
|GlaxoSmithKline plc (GSK.L)||1,340.50p||+9.50|
|Eli Lilly and Co (LLY.N)||$83.19||-0.55|
|Arena Pharmaceuticals, Inc. (ARNA.OQ)||$2.71||+0.06|
|Orexigen Therapeutics, Inc. (OREX.OQ)||$2.89||+0.13|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (VVUS). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC
Provider : Ford Investor Services, Inc.
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of VIVUS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider : Jefferson Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.